检索结果-南通市图书馆

中国药理学会药物临床试验专业委员会首届学术研讨会

作者：何国东周志凌王曦培郑志杰麦丽萍钟诗龙杨敏余细勇广东省人民医院(广东省医学科学院)临床药理研究部广东省心血管病研究所

目的:建立一个快速、高选择性的高效液相色谱串联质谱(LC-MS/MS)方法,用于人体药动学研究中测定人血浆中依菲巴特的含量。方法:以EPM-05为内标,采用固相萃取法提取血浆中依菲巴特与内标。采用Ultimate XB-C18(4.6 mm×1 50 mm.5μm),流... 详细信息

目的:建立一个快速、高选择性的高效液相色谱串联质谱(LC-MS/MS)方法,用于人体药动学研究中测定人血浆中依菲巴特的含量。方法:以EPM-05为内标,采用固相萃取法提取血浆中依菲巴特与内标。采用Ultimate XB-C18(4.6 mm×1 50 mm.5μm),流动相乙腈-水(10 mmol/L乙酸铵缓冲盐,0.1%甲酸)(32∶68,v/v),流速为0.5 mL/min。采用ESI正离子模式,MRM扫描方式,选用离子对m/z832.6-->646.4与m/z 931.6->159.4分别对依菲巴特和内标进行定量分析。结果:标准曲线范围为1-1000 ng/mL,最低定量下限为1 ng/mL。日内及日间精密度在13.3%以内,准确度±7.6%以内,依菲巴特及内标的提取回收率均大于78%,血浆中依菲巴特及内标的基质效应均在±15%以内。结论:本LC-MS/MS方法高效、灵敏度高,成功应用于8名健康志愿者静脉给药依菲巴特(45μg/kg)的药代动力学特征研究。

关键词：高效液相色谱串联质谱依菲巴特方法学验证

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

经皮冠状动脉介入治疗抗血小板治疗现状和进展

引用

中国医学前沿杂志（电子版） 2011年第3期3卷 43-49页

作者：陈明王茜婷北京大学第一医院心内科北京100034

随着医学技术的不断发展,经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI) 成为现今对冠状动脉粥样硬化性心脏病(冠心病)最行之有效的治疗手段。自PCI 技术开展至今的20 余年时间里,有大量的患者受益,但支架内血栓形成... 详细信息

随着医学技术的不断发展,经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI) 成为现今对冠状动脉粥样硬化性心脏病(冠心病)最行之有效的治疗手段。自PCI 技术开展至今的20 余年时间里,有大量的患者受益,但支架内血栓形成和再狭窄仍然是制约PCI 发展的难题。支架置入对血管壁造成损伤,使胶原暴露,血小板活化、聚集及黏附在损伤局部,引起支架内血栓形成;或由于异物及损伤诱发炎性反应,血管内膜增生,血小板聚集,造成支架内再狭窄,这均会导致严重心血管事件的发生[1] 。因此,强化抗血小板治疗,预防血栓事件成为目前心脏介入学科医生关注的热点。

关键词：氯吡格雷抵抗患者 STEMI 替罗非班依替巴肽阿司匹林替洛非巴依菲巴特乙酰水杨酸抗血小板治疗 PCI 经皮冠状动脉介入治疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

ST段抬高心肌梗死患者冠状动脉内应用依替巴肽的效果

引用

世界核心医学期刊文摘(心脏病学分册) 2006年第4期 44-45页

作者： Pinto D.S. Kirtane A.J. Ruocco N.A. C.M. Gibson 王海玲 Beth Israel Deaconess Medical Center Division of Cardiology Boston MA United States Dr.

Distal embolization of atherothrombotic material during primary percutaneous coronary intervention(PCI)is associated with impaired myocardial perfusion, abnormal left ventricular function, and higher mortality. At high local concentration s, glycoprotein IIb/IIIa receptor antagonists have been demonstrated to promote clot disaggregation in vitro. Intracoronary administration of eptifibatide in vi vo may increase local drug concentration by several orders of magnitude and prom ote clot disaggregation with a minimal increase in systemic drug concentrations. We hypothesized that intracoronary administration of eptifibatide before primar y PCI for ST-elevation myocardial infarction would be safe and would be associa ted with high rates of normal myocardial perfusion. Clinical and angiographic da ta were pooled from patients who underwent primary PCI and received intracoronar y eptifibatide as part of clinical practice. In-hospital adverse events were co llected retrospectively. No deaths, urgent revascularizations, or reinfarctions were observed among the 59 patients who were treated with intracoronary eptifiba tide. There were no Thrombolysis In Myocardial Infarction(TIMI)major bleeding ev ents. Two TIMI minor bleeding events were noted. Normal TIMI myocardial perfusio n grade 3 flow after PCI was noted in 54.4%of patients. No adverse events,incl uding arrhythmias, were noted during intracoronary eptifibatide administration. In conclusion, intracoronary eptifibatide can be administered safely during prim ary PCI and is associated with few adverse events. Relatively high rates of norm al myocardial perfusion were observed after primary PCI with adjunctive intracor onary eptifibatide. Further prospective randomized trials are warranted to evalu ate the efficacy and safety of intracoronary eptifibatide.

关键词：冠状动脉内依替巴肽依菲巴特心肌梗死患者 ST

来源：

同方期刊数据库评论